
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Galindo hopes that less patients will be diagnosed with advanced chronic kidney disease if we use the right glucose-lowering agents in the earliest stages.
Pharmacy Times spoke to Rodolfo Galindo, MD, associate professor at the Emory School of Medicine, about his session at the ASN 2021 conference titled "Use of Glucose-Lowering Agents and Glycemic Monitoring in Advanced CKD.”
Galindo hopes that less patients will be diagnosed with advanced chronic kidney disease if we use the right glucose-lowering agents in the earliest stages.






